Emerging insights into PPARα′s role in lean metabolic dysfunction-associated steatotic liver disease: Implications for targeted therapies
Authors:
- Yafei YangYYYafei Yang
- Furong ZhangFZFurong Zhang
- Zhuang PengZPZhuang Peng
- Yafei WuYWYafei Wu
- Ling LiLLLing Li
- Zixia ShenZSZixia Shen
- Qifa YeQYQifa Ye
- Jiang YueJYJiang Yue
- Shufang NaSNShufang Na
Open Access
- 19 June 2026
- journal article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (10) , 6462-6506
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China
This publication has 442 references indexed in Scilit:
- Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol‐Inducible Cytochrome P450‐2E1–Mediated Oxidative and Nitrative StressHepatology, 2019
- The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in miceHepatology, 2014
- Resveratrol and Its Metabolites Bind to PPARsChemBioChem, 2014
- High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinaseHepatology, 2013
- Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits HypothesisHepatology, 2010
- Dehydroabietic acid, a diterpene, improves diabetes and hyperlipidemia in obese diabetic KK‐Ay miceBioFactors, 2009
- Auraptene, a citrus fruit compound, regulates gene expression as a PPARα agonist in HepG2 hepatocytesBioFactors, 2008
- Effects of a Potent and Selective PPAR-α Agonist in Patients With Atherogenic Dyslipidemia or HypercholesterolemiaJAMA, 2007
- Cooperative Clofibrate Trial1979
- Clofibrate and Niacin in Coronary Heart DiseaseJAMA, 1975